Patents by Inventor Bernard B. C. Lim
Bernard B. C. Lim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9585708Abstract: Some embodiments of a medical instrument can be configured to reduce the formation of coagulum by delivering a negative charge bias to conductive surfaces that interface with blood or bodily tissue during a medical procedure. The application of the negative charge at the instrument-blood interface can reduce the fibrinogen deposition and the formation of coagulum because fibrinogen molecules in general are negatively charged at neutral pH levels. In addition, some embodiments of the instrument may be configured to irrigate the instrument-blood interface with RGD/ClfA peptides, a bicarbonate solution (or other high pH solution), or both to further repel the fibrinogen and thereby inhibit the formation of coagulum. Accordingly, some embodiments of the medical instrument can substantially reduce the risks of thromboembolism during particular medical procedures.Type: GrantFiled: February 3, 2016Date of Patent: March 7, 2017Assignee: Mayo Foundation for Medical Education and ResearchInventors: Samuel J. Asirvatham, Arshad Jahangir, Bernard B. C. Lim, Kalpathi L. Venkatachalam
-
Publication number: 20160151105Abstract: Some embodiments of a medical instrument can be configured to reduce the formation of coagulum by delivering a negative charge bias to conductive surfaces that interface with blood or bodily tissue during a medical procedure. The application of the negative charge at the instrument-blood interface can reduce the fibrinogen deposition and the formation of coagulum because fibrinogen molecules in general are negatively charged at neutral pH levels. In addition, some embodiments of the instrument may be configured to irrigate the instrument-blood interface with RGD/ClfA peptides, a bicarbonate solution (or other high pH solution), or both to further repel the fibrinogen and thereby inhibit the formation of coagulum. Accordingly, some embodiments of the medical instrument can substantially reduce the risks of thromboembolism during particular medical procedures.Type: ApplicationFiled: February 3, 2016Publication date: June 2, 2016Inventors: Samuel J. Asirvatham, Arshad Jahangir, Bernard B.C. Lim, Kalpathi L. Venkatachalam
-
Patent number: 9271786Abstract: Some embodiments of a medical instrument can be configured to reduce the formation of coagulum by delivering a negative charge bias to conductive surfaces that interface with blood or bodily tissue during a medical procedure. The application of the negative charge at the instrument-blood interface can reduce the fibrinogen deposition and the formation of coagulum because fibrinogen molecules in general are negatively charged at neutral pH levels. In addition, some embodiments of the instrument may be configured to irrigate the instrument-blood interface with RGD/ClfA peptides, a bicarbonate solution (or other high pH solution), or both to further repel the fibrinogen and thereby inhibit the formation of coagulum. Accordingly, some embodiments of the medical instrument can substantially reduce the risks of thromboembolism during particular medical procedures.Type: GrantFiled: July 14, 2014Date of Patent: March 1, 2016Assignee: Mayo Foundation for Medical Education and ResearchInventors: Samuel J. Asirvatham, Arshad Jahangir, Bernard B. C. Lim, Kalpathi L. Venkatachalam
-
Publication number: 20140324040Abstract: Some embodiments of a medical instrument can be configured to reduce the formation of coagulum by delivering a negative charge bias to conductive surfaces that interface with blood or bodily tissue during a medical procedure. The application of the negative charge at the instrument-blood interface can reduce the fibrinogen deposition and the formation of coagulum because fibrinogen molecules in general are negatively charged at neutral pH levels. In addition, some embodiments of the instrument may be configured to irrigate the instrument-blood interface with RGD/ClfA peptides, a bicarbonate solution (or other high pH solution), or both to further repel the fibrinogen and thereby inhibit the formation of coagulum. Accordingly, some embodiments of the medical instrument can substantially reduce the risks of thromboembolism during particular medical procedures.Type: ApplicationFiled: July 14, 2014Publication date: October 30, 2014Inventors: Samuel J. Asirvatham, Arshad Jahangir, Bernard B.C. Lim, Kalpathi L. Venkatachalam
-
Patent number: 8790338Abstract: Some embodiments of a medical instrument can be configured to reduce the formation of coagulum by delivering a negative charge bias to conductive surfaces that interface with blood or bodily tissue during a medical procedure. The application of the negative charge at the instrument-blood interface can reduce the fibrinogen deposition and the formation of coagulum because fibrinogen molecules in general are negatively charged at neutral pH levels. In addition, some embodiments of the instrument may be configured to irrigate the instrument-blood interface with RGD/ClfA peptides, a bicarbonate solution (or other high pH solution), or both to further repel the fibrinogen and thereby inhibit the formation of coagulum. Accordingly, some embodiments of the medical instrument can substantially reduce the risks of thromboembolism during particular medical procedures.Type: GrantFiled: February 13, 2012Date of Patent: July 29, 2014Assignee: Mayo Foundation for Medical Education and ResearchInventors: Samuel J. Asirvatham, Arshad Jahangir, Bernard B. C. Lim, Kalpathi L. Venkatachalam
-
Patent number: 8409192Abstract: Some embodiments of a medical instrument can be configured to reduce the formation of coagulum by delivering a negative charge bias to conductive surfaces that interface with blood or bodily tissue during a medical procedure. The application of the negative charge at the instrument-blood interface can reduce the fibrinogen deposition and the formation of coagulum because fibrinogen molecules in general are negatively charged at neutral pH levels. In addition, some embodiments of the instrument may be configured to irrigate the instrument-blood interface with RGD/ClfA peptides, a bicarbonate solution (or other high pH solution), or both to further repel the fibrinogen and thereby inhibit the formation of coagulum. Accordingly, some embodiments of the medical instrument can substantially reduce the risks of thromboembolism during particular medical procedures.Type: GrantFiled: February 20, 2009Date of Patent: April 2, 2013Assignee: Mayo Foundation for Medical Education and ResearchInventors: Samuel J. Asirvatham, Arshad Jahangir, Bernard B. C. Lim, Kalpathi L. Venkatachalam
-
Publication number: 20120150171Abstract: Some embodiments of a medical instrument can be configured to reduce the formation of coagulum by delivering a negative charge bias to conductive surfaces that interface with blood or bodily tissue during a medical procedure. The application of the negative charge at the instrument-blood interface can reduce the fibrinogen deposition and the formation of coagulum because fibrinogen molecules in general are negatively charged at neutral pH levels. In addition, some embodiments of the instrument may be configured to irrigate the instrument-blood interface with RGD/C1fA peptides, a bicarbonate solution (or other high pH solution), or both to further repel the fibrinogen and thereby inhibit the formation of coagulum. Accordingly, some embodiments of the medical instrument can substantially reduce the risks of thromboembolism during particular medical procedures.Type: ApplicationFiled: February 13, 2012Publication date: June 14, 2012Inventors: Samuel J. Asirvatham, Arshad Jahangir, Bernard B.C. Lim, Kalpathi L. Venkatachalam
-
Patent number: 8162936Abstract: Some embodiments of a medical instrument can be configured to reduce the formation of coagulum by delivering a negative charge bias to conductive surfaces that interface with blood or bodily tissue during a medical procedure. The application of the negative charge at the instrument-blood interface can reduce the fibrinogen deposition and the formation of coagulum because fibrinogen molecules in general are negatively charged at neutral pH levels. In addition, some embodiments of the instrument may be configured to irrigate the instrument-blood interface with RGD/ClfA peptides, a bicarbonate solution (or other high pH solution), or both to further repel the fibrinogen and thereby inhibit the formation of coagulum. Accordingly, some embodiments of the medical instrument can substantially reduce the risks of thromboembolism during particular medical procedures.Type: GrantFiled: February 20, 2009Date of Patent: April 24, 2012Assignee: Mayo Foundation for Medical Education and ResearchInventors: Samuel J. Asirvatham, Arshad Jahangir, Bernard B. C. Lim, Kalpathi L. Venkatachalam
-
Publication number: 20090187187Abstract: Some embodiments of a medical instrument can be configured to reduce the formation of coagulum by delivering a negative charge bias to conductive surfaces that interface with blood or bodily tissue during a medical procedure. The application of the negative charge at the instrument-blood interface can reduce the fibrinogen deposition and the formation of coagulum because fibrinogen molecules in general are negatively charged at neutral pH levels. In addition, some embodiments of the instrument may be configured to irrigate the instrument-blood interface with RGD/ClfA peptides, a bicarbonate solution (or other high pH solution), or both to further repel the fibrinogen and thereby inhibit the formation of coagulum. Accordingly, some embodiments of the medical instrument can substantially reduce the risks of thromboembolism during particular medical procedures.Type: ApplicationFiled: February 20, 2009Publication date: July 23, 2009Applicant: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCHInventors: Samuel J. Asirvatham, Arshad Jahangir, Bernard B.C. Lim, Kalpathi L. Venkatachalam